ERBB2 and breast carcinoma: Binding to an epitope that does not activate HER2 may actually provide a therapeutic advantage for the 2Rs15d Nb as it does not compete with trastuzumab (a commonly prescribed mAb used in the treatment of breast cancer) for HER2 binding, allowing radiolabeled 2Rs15d to be used in a combination therapy protocol [112].